Brief: Inmune Bio Announces Submission Of Phase 2 Mindful Trial Results In Alzheimer’S
29/09/2025 13:15
Sept 29 (Reuters) - INmune Bio Inc INMB.O: INMUNE BIO ANNOUNCES SUBMISSION OF PHASE 2 MINDFUL TRIAL RESULTS IN ALZHEIMER’S DISEASE TO NPJ DEMENTIA, A NATURE PORTFOLIO JOURNAL Source text: ID:nGNX414TG7 Further company coverage: INMB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview